Thomas F. Isett
Vorstandsvorsitzender bei Transposagen Biopharmaceuticals, Inc.
Vermögen: 1 428 $ am 31.05.2024
Profil
Thomas F.
Isett is currently the Chief Executive Officer at Transposagen Biopharmaceuticals, Inc. and Chairman & Chief Executive Officer at iBio CDMO LLC.
Previously, he served as the Chief Executive Officer & Director at iBio, Inc. from 2019 to 2022.
He also held positions as the Chief Executive Officer at Commence Biologics, Inc., Managing Director at i.e.
Advising LLC, Vice President-Advanced Bioprocessing at Becton, Dickinson & Co., and General Manager-BioProcess at GE Aerospace.
From 2009 to 2012, he was the Head-Cell Processing Technologies at Lonza AG.
Mr. Isett completed his undergraduate degree at Drexel University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IBIO, INC.
0,01% | 25.10.2023 | 600 ( 0,01% ) | 1 428 $ | 31.05.2024 |
Aktive Positionen von Thomas F. Isett
| Unternehmen | Position | Beginn |
|---|---|---|
Transposagen Biopharmaceuticals, Inc.
 Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Vorstandsvorsitzender | 01.08.2017 |
iBio CDMO LLC
 iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Thomas F. Isett
| Unternehmen | Position | Ende |
|---|---|---|
| IBIO, INC. | Vorstandsvorsitzender | 01.12.2022 |
Lonza AG
 Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Corporate Officer/Principal | 01.01.2012 |
| BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | 01.01.2009 |
| Commence Biologics, Inc. | Vorstandsvorsitzender | - |
| i.e. Advising LLC | Vorstandsvorsitzender | - |
Ausbildung von Thomas F. Isett
| Drexel University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BECTON, DICKINSON AND COMPANY | Health Technology |
| GE AEROSPACE | Producer Manufacturing |
| IBIO, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Health Technology |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Health Technology |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Health Technology |
| i.e. Advising LLC | |
| Commence Biologics, Inc. |
